KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash from Investing Activities (2016 - 2025)

Abbott Laboratories' Cash from Investing Activities history spans 17 years, with the latest figure at -$913.0 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 5.43% year-over-year to -$913.0 million; the TTM value through Dec 2025 reached -$2.4 billion, down 3.59%, while the annual FY2025 figure was -$2.4 billion, 3.59% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$913.0 million at Abbott Laboratories, down from -$457.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$264.0 million in Q2 2021 and bottomed at -$1.2 billion in Q2 2023.
  • The 5-year median for Cash from Investing Activities is -$533.0 million (2022), against an average of -$582.0 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 359.47% in 2023 before it surged 62.65% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$671.0 million in 2021, then grew by 5.81% to -$632.0 million in 2022, then tumbled by 30.38% to -$824.0 million in 2023, then decreased by 5.1% to -$866.0 million in 2024, then fell by 5.43% to -$913.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Cash from Investing Activities are -$913.0 million (Q4 2025), -$457.0 million (Q3 2025), and -$582.0 million (Q2 2025).